These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 21439476)

  • 1. Jak1 has a dominant role over Jak3 in signal transduction through γc-containing cytokine receptors.
    Haan C; Rolvering C; Raulf F; Kapp M; Drückes P; Thoma G; Behrmann I; Zerwes HG
    Chem Biol; 2011 Mar; 18(3):314-23. PubMed ID: 21439476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of a potent Janus kinase 3 inhibitor with high selectivity within the Janus kinase family.
    Thoma G; Nuninger F; Falchetto R; Hermes E; Tavares GA; Vangrevelinghe E; Zerwes HG
    J Med Chem; 2011 Jan; 54(1):284-8. PubMed ID: 21155605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities.
    Losdyck E; Hornakova T; Springuel L; Degryse S; Gielen O; Cools J; Constantinescu SN; Flex E; Tartaglia M; Renauld JC; Knoops L
    J Biol Chem; 2015 Nov; 290(48):29022-34. PubMed ID: 26446793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Receptor expression is essential for proliferation induced by dimerized Jak kinases.
    Fujii H
    Biochem Biophys Res Commun; 2008 Jun; 370(4):557-60. PubMed ID: 18381062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 3-Amido pyrrolopyrazine JAK kinase inhibitors: development of a JAK3 vs JAK1 selective inhibitor and evaluation in cellular and in vivo models.
    Soth M; Hermann JC; Yee C; Alam M; Barnett JW; Berry P; Browner MF; Frank K; Frauchiger S; Harris S; He Y; Hekmat-Nejad M; Hendricks T; Henningsen R; Hilgenkamp R; Ho H; Hoffman A; Hsu PY; Hu DQ; Itano A; Jaime-Figueroa S; Jahangir A; Jin S; Kuglstatter A; Kutach AK; Liao C; Lynch S; Menke J; Niu L; Patel V; Railkar A; Roy D; Shao A; Shaw D; Steiner S; Sun Y; Tan SL; Wang S; Vu MD
    J Med Chem; 2013 Jan; 56(1):345-56. PubMed ID: 23214979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diamino-1,2,4-triazole derivatives are selective inhibitors of TYK2 and JAK1 over JAK2 and JAK3.
    Malerich JP; Lam JS; Hart B; Fine RM; Klebansky B; Tanga MJ; D'Andrea A
    Bioorg Med Chem Lett; 2010 Dec; 20(24):7454-7. PubMed ID: 21106455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition.
    Telliez JB; Dowty ME; Wang L; Jussif J; Lin T; Li L; Moy E; Balbo P; Li W; Zhao Y; Crouse K; Dickinson C; Symanowicz P; Hegen M; Banker ME; Vincent F; Unwalla R; Liang S; Gilbert AM; Brown MF; Hayward M; Montgomery J; Yang X; Bauman J; Trujillo JI; Casimiro-Garcia A; Vajdos FF; Leung L; Geoghegan KF; Quazi A; Xuan D; Jones L; Hett E; Wright K; Clark JD; Thorarensen A
    ACS Chem Biol; 2016 Dec; 11(12):3442-3451. PubMed ID: 27791347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impaired IL-7 signaling may explain a case of atypical JAK3-SCID.
    Li J; Nara H; Rahman M; Juliana FM; Araki A; Asao H
    Cytokine; 2010 Feb; 49(2):221-8. PubMed ID: 19889552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. JAK3 inhibition significantly attenuates psoriasiform skin inflammation in CD18 mutant PL/J mice.
    Chang BY; Zhao F; He X; Ren H; Braselmann S; Taylor V; Wicks J; Payan DG; Grossbard EB; Pine PR; Bullard DC
    J Immunol; 2009 Aug; 183(3):2183-92. PubMed ID: 19596999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute lymphoblastic leukemia-associated JAK1 mutants activate the Janus kinase/STAT pathway via interleukin-9 receptor alpha homodimers.
    Hornakova T; Staerk J; Royer Y; Flex E; Tartaglia M; Constantinescu SN; Knoops L; Renauld JC
    J Biol Chem; 2009 Mar; 284(11):6773-81. PubMed ID: 19139102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ATP-mediated kinome selectivity: the missing link in understanding the contribution of individual JAK Kinase isoforms to cellular signaling.
    Thorarensen A; Banker ME; Fensome A; Telliez JB; Juba B; Vincent F; Czerwinski RM; Casimiro-Garcia A
    ACS Chem Biol; 2014 Jul; 9(7):1552-8. PubMed ID: 24814050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. JAK3, STAT, and MAPK signaling pathways as novel molecular targets for the tyrphostin AG-490 regulation of IL-2-mediated T cell response.
    Wang LH; Kirken RA; Erwin RA; Yu CR; Farrar WL
    J Immunol; 1999 Apr; 162(7):3897-904. PubMed ID: 10201908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 - 2012.
    Dymock BW; See CS
    Expert Opin Ther Pat; 2013 Apr; 23(4):449-501. PubMed ID: 23367873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model.
    Degryse S; de Bock CE; Cox L; Demeyer S; Gielen O; Mentens N; Jacobs K; Geerdens E; Gianfelici V; Hulselmans G; Fiers M; Aerts S; Meijerink JP; Tousseyn T; Cools J
    Blood; 2014 Nov; 124(20):3092-100. PubMed ID: 25193870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Janus kinases in interleukin-2-mediated signaling: JAK1 and JAK3 are differentially regulated by tyrosine phosphorylation.
    Liu KD; Gaffen SL; Goldsmith MA; Greene WC
    Curr Biol; 1997 Nov; 7(11):817-26. PubMed ID: 9382798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective functional inhibition of JAK-3 is sufficient for efficacy in collagen-induced arthritis in mice.
    Lin TH; Hegen M; Quadros E; Nickerson-Nutter CL; Appell KC; Cole AG; Shao Y; Tam S; Ohlmeyer M; Wang B; Goodwin DG; Kimble EF; Quintero J; Gao M; Symanowicz P; Wrocklage C; Lussier J; Schelling SH; Hewet AG; Xuan D; Krykbaev R; Togias J; Xu X; Harrison R; Mansour T; Collins M; Clark JD; Webb ML; Seidl KJ
    Arthritis Rheum; 2010 Aug; 62(8):2283-93. PubMed ID: 20506481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective inhibitors of the Janus kinase Jak3--Are they effective?
    Thoma G; Drückes P; Zerwes HG
    Bioorg Med Chem Lett; 2014 Oct; 24(19):4617-4621. PubMed ID: 25217444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delineation of the regions of interleukin-2 (IL-2) receptor beta chain important for association of Jak1 and Jak3. Jak1-independent functional recruitment of Jak3 to Il-2Rbeta.
    Zhu MH; Berry JA; Russell SM; Leonard WJ
    J Biol Chem; 1998 Apr; 273(17):10719-25. PubMed ID: 9553136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Signalling by cytokines interacting with the interleukin-2 receptor gamma chain.
    Demoulin JB; Renauld JC
    Cytokines Cell Mol Ther; 1998 Dec; 4(4):243-56. PubMed ID: 10068058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of JAK3, but not JAK1, is critical for IL-2-induced proliferation and STAT5 recruitment by a COOH-terminal region of the IL-2 receptor beta-chain.
    Kirken RA; Rui H; Malabarba MG; Howard OM; Kawamura M; O'Shea JJ; Farrar WL
    Cytokine; 1995 Oct; 7(7):689-700. PubMed ID: 8580378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.